Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia

OBJECTIVES: Survival outcomes from a single‐arm phase 2 blinatumomab study in patients with minimal residual disease (MRD)‐positive B‐cell precursor (BCP)‐acute lymphoblastic leukaemia (ALL) were compared with those receiving standard of care (SOC) in a historic data set. METHODS: The primary analys...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Haematol
Autors principals: Gökbuget, Nicola, Dombret, Hervé, Giebel, Sebastian, Brüggemann, Monika, Doubek, Michael, Foa, Robin, Hoelzer, Dieter, Kim, Christopher, Martinelli, Giovanni, Parovichnikova, Elena, Maria Ribera, Josep, Schoonen, Marieke, Tuglus, Catherine, Zugmaier, Gerhard, Bassan, Renato
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7079006/
https://ncbi.nlm.nih.gov/pubmed/31876009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13375
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars